<DOC>
	<DOCNO>NCT02533973</DOCNO>
	<brief_summary>A phase 4 trial compare safety efficacy treatment Xamiol® gel ( calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g ( dipropionate ) ) daily ( require ) Daivonex® scalp solution ( calcipotriol 50 mcg/g ) twice daily ( require ) Chinese subject scalp psoriasis</brief_summary>
	<brief_title>Long-term Treatment Scalp Psoriasis With Xamiol® Gel Large Adult Chinese Population</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>1 . Signed date informed consent obtain . 2 . Subjects either gender 18 year age . 3 . At visit 1 , clinical diagnosis scalp psoriasis : investigator 's assessment clinical sign scalp least ≥ 2 one clinical sign , redness , thickness , scaliness , least 1 two clinical sign , total score ≥ 4 extent 10 % total scalp area least mild severity accord investigator 's global assessment 4 . Clinical sign psoriasis vulgaris trunk and/or limb , subject earlier diagnosed psoriasis vulgaris trunk and/or limb . 5 . Female childbearing potential use reliable method contraception least 1 month trial start course trial ( e.g. , oral contraceptive pill , intrauterine device , contraceptive patch , implantable contraception , condom ) female nonchildbearing potential ( i.e . postmenopausal ( absence menstrual bleeding 2 year ) , hysterectomy , bilateral ovariectomy , tubal section/ligation ) . 1 . Current diagnosis guttate , erythrodermic , exfoliative , pustular psoriasis . 2 . Subjects follow condition present scalp area : viral lesion , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , acne rosacea , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , ulcer , wound . 3 . Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation trial : etanercept ( Yisaipu ) within 4 week prior randomisation infliximab ( Remicade ) within 2 month prior randomisation product : within 4 weeks/5 halflives ( whichever longer ) prior randomisation 4 . Systemic treatment therapy possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , methotrexate , ciclosporin immunosuppressant 's , TCM [ ( traditional Chinese Medicine ) ] ) within 4 week prior randomisation trial . 5 . PUVA therapy within 4 week prior randomisation trial . 6 . UVB therapy within 2 week prior randomisation trial . 7 . Therapies within 2 week prior randomisation trial : Topical treatment body psoriasis potent ( WHO group IV ) corticosteroids Topical treatment face psoriasis potent potent ( WHO group III IV ) corticosteroids Any topical treatment scalp ( except nonsteroid medicate shampoos emollient ) 8 . Known suspected renal insufficiency hepatic disorder severe heart disease . 9 . Clinical sign symptoms Cushing 's disease Addison 's disease . 10 . Known suspected hypersensitivity component ( ) IMPs 11 . Current participation interventional clinical trial 12 . Subjects receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4 weeks/5 halflives ( whichever longer ) prior randomisation . 13 . Previously participate clinical trial within 4 week prior randomisation . 14 . In opinion ( sub ) investigator , subject unlikely comply clinical trial protocol ( e.g . due alcoholism , drug addiction psychotic state ) . 15 . Females pregnant , childbearing potential wish become pregnant trial , breastfeed . 16 . Females childbearing potential positive urine pregnancy test visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>